Core Viewpoint - Venus Concept Inc. has announced its decision to voluntarily delist its common stock from the NASDAQ Capital Market and deregister its common stock with the SEC, citing that the costs of compliance outweigh the benefits for the company and its shareholders [1][2]. Delisting and Deregistration - The company is compliant with Nasdaq listing requirements but has determined that the resources needed for SEC reporting obligations are excessive compared to the benefits [2]. - Venus Concept has notified Nasdaq of its intent to delist and deregister, planning to file a Form 25 on or about January 30, 2026, with the last trading day expected to be around February 6, 2026 [3]. - A Form 15 will be filed on or about February 9, 2026, which will suspend the company's obligation to file periodic reports with the SEC [3]. Management's Perspective - The Board of Directors believes that this decision is in the best interests of the company and its shareholders, as it will reduce compliance costs and support the execution of the company's turnaround plan [4]. - The CEO of Venus Concept emphasized the collaboration with Madryn Asset Management to position the company for long-term financial success [4]. Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products, reaching over 60 countries [5]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare industry investors [5].

Company Overview - Venus Concept Inc. is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products for aesthetic and hair restoration [4] - The company operates in over 60 countries and has 9 direct markets, showcasing its extensive reach in the industry [4] - Venus Concept's product portfolio includes various aesthetic device platforms and hair restoration systems, such as NeoGraft® and the ARTAS iX® Robotic Hair Restoration system [4] Financial Results Announcement - The company will release its second quarter fiscal year 2025 financial results after market close on August 14, 2025 [1] - A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results and answer questions [2] - For those unable to attend, a replay of the call will be available for two weeks, and a webcast will be archived on the company's investor relations website [3] Investor Relations - Investor relations contact for Venus Concept is managed by ICR Healthcare, with Mike Piccinino, CFA, as the point of contact [5]

Core Points - Venus Concept Inc. has announced a registered direct offering of 434,720 shares of common stock at a price of $2.65 per share, with expected gross proceeds of approximately $1.15 million [1][3] - The company will also issue unregistered short-term warrants to purchase up to 869,440 shares at the same exercise price, potentially generating an additional $2.3 million if fully exercised [1][3] - The offering is expected to close around June 9, 2025, pending customary closing conditions [1] Offering Details - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The shares are being offered under a "shelf" registration statement effective since November 1, 2024, and a final prospectus supplement will be filed with the SEC [4] - The unregistered short-term warrants are offered in a private placement and have not been registered under the Securities Act [5] Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a range of minimally invasive and non-invasive products across over 60 countries [7] - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare growth equity investors [7]

Core Viewpoint - Venus Concept Inc. reported a decline in financial performance for the first quarter of 2025, with total revenue decreasing by 22% year-over-year, attributed to challenging market conditions and timing of new system adoptions [5][10]. Financial Results Summary - Total revenue for Q1 2025 was $13.6 million, down from $17.5 million in Q1 2024, reflecting a decrease of $3.8 million or 21.9% [5][6]. - Revenue breakdown showed a 29.3% decrease in international revenue and a 16.5% decrease in U.S. revenue [6]. - Revenue from products—systems decreased by 25%, and lease systems revenue also saw a 25% decline [6][7]. - Gross profit for Q1 2025 was $8.8 million, a decrease of 25% compared to Q1 2024, with a gross margin of 64.2% [7][10]. - Operating expenses decreased by 6% year-over-year to $18.3 million, driven by reductions in general and administrative, selling and marketing, and research and development expenses [8][9]. - The company reported a GAAP net loss of $12.4 million for Q1 2025, compared to a net loss of $9.8 million in Q1 2024 [10][11]. Management Commentary - The CEO emphasized solid execution despite a challenging environment and indicated a focus on managing cash burn and making targeted investments for long-term growth [3][4]. - The company enhanced its balance sheet with a new bridge loan amendment and two equity capital transactions, indicating validation from investors regarding its potential value creation [3][4]. Cash Position and Debt - As of March 31, 2025, the company had cash and cash equivalents of $3.2 million and total debt obligations of approximately $35.5 million, a decrease from $39.7 million at the end of 2024 [11][12]. - The company is currently not providing full-year 2025 financial guidance due to ongoing evaluations of strategic alternatives and potential trade disruptions [12]. Conference Call Details - Management will host a conference call to discuss the quarterly results, providing an opportunity for questions and answers [13].